Novel small-molecule therapeutics development leverages boron chemistry
Anacor Pharmaceuticals developed and commercialized novel therapeutics with its boron chemistry platform. The foundation’s investment helps support the development of preclinical drug candidates.
- Focus areas
- Life Sciences
- Investment type
- Direct equity
- Status
- Exit
- Initial investment
- Public
- Partnered in
- 2013
- Headquarters
- USA
- Portfolio news
- In 2016, Anacor was acquired by Pfizer
More about our work
Our focus
We embrace science and technology innovations that solve old problems in new ways, challenge status quos, and build on past breakthroughs. Our six domains of focus comprise 40+ program strategies across the foundation’s nearly $9B annual charitable support.
Investment Approach
How the Strategic Investment Fund is fostering partnerships with the private sector to leverage the globe’s most groundbreaking global innovations for societal good.
Our Team
The SIF Investment Committee brings depth of experience to global investment programs, with a proven track record of innovation across sectors and scale.